Alexander Disease (AxD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033


 

Alexander disease is an autosomal dominant disorder caused by the mutations in this protein led to decreased GFAP solubility. They triggered the formation of inclusion bodies, such as the Rosenthal fibers, leading to the accumulation of abnormal astrocytes and myelin pallor throughout the affected brain tissue. Three forms of Alexander disease are diagnosed: around 51% of infants with a typical presentation before 6 months of age, 23% of juveniles, and 24% of adults. The typical infantile form presents with macrocephaly, failure to thrive, difficulty swallowing, loss of intellectual/motor milestones, lower extremity weakness, ataxia, seizures, and occasionally hydrocephalus. The juvenile and adult forms are dominated more by ataxia and bulbar/ pseudobulbar symptoms, as well as the seizures and lower extremity weakness seen in the infantile form. Typical imaging characteristics include frontal-predominant subcortical to periventricular white matter T2 hyperintensity with swelling of the overlying gyri, swelling of the fornix and optic nerves, periventricular areas of T1/T2 shortening, profound gray matter signal increase or atrophy, dentate hilum signal increase, brainstem (midbrain/medulla) signal increase, and enhancement of involved areas. Progression to atrophy and occasionally white matter cavitation are common.

 

Thelansis’s “Alexander Disease (AxD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Alexander Disease (AxD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Alexander Disease (AxD) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Alexander Disease (AxD) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Alexander Disease (AxD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Comments

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033